Summit Cash Per Share from 2010 to 2024

SMMT Stock  USD 19.00  0.58  3.15%   
Summit Therapeutics Cash Per Share yearly trend continues to be comparatively stable with very little volatility. Cash Per Share is likely to outpace its year average in 2024. From the period from 2010 to 2024, Summit Therapeutics Cash Per Share quarterly data regression had r-value of  0.51 and coefficient of variation of  80.98. View All Fundamentals
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
0.30056185
Current Value
0.45
Quarterly Volatility
0.43045321
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Summit Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Summit Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 17.3 M or Selling General Administrative of 31.8 M, as well as many indicators such as Price To Sales Ratio of 1.3 K, Dividend Yield of 0.0 or PTB Ratio of 19.78. Summit financial statements analysis is a perfect complement when working with Summit Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Summit Therapeutics Correlation against competitors.

Latest Summit Therapeutics' Cash Per Share Growth Pattern

Below is the plot of the Cash Per Share of Summit Therapeutics PLC over the last few years. It is Summit Therapeutics' Cash Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Summit Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.61 X10 Years Trend
Slightly volatile
   Cash Per Share   
       Timeline  

Summit Cash Per Share Regression Statistics

Arithmetic Mean0.53
Geometric Mean0.32
Coefficient Of Variation80.98
Mean Deviation0.29
Median0.43
Standard Deviation0.43
Sample Variance0.19
Range1.7954
R-Value0.51
Mean Square Error0.15
R-Squared0.26
Significance0.05
Slope0.05
Total Sum of Squares2.59

Summit Cash Per Share History

2024 0.45
2023 0.3
2022 1.8
2021 0.78
2020 0.96
2018 0.41
2017 0.44

About Summit Therapeutics Financial Statements

Summit Therapeutics shareholders use historical fundamental indicators, such as Cash Per Share, to determine how well the company is positioned to perform in the future. Although Summit Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Summit Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Summit Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Cash Per Share 0.30  0.45 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Summit Stock Analysis

When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.